Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $92
Portfolio Pulse from Benzinga Newsdesk
Barrington Research maintains an Outperform rating on LeMaitre Vascular (NASDAQ:LMAT) and raises the price target from $79 to $92.
August 02, 2024 | 10:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barrington Research has maintained its Outperform rating on LeMaitre Vascular and increased the price target from $79 to $92, indicating strong confidence in the company's future performance.
The increase in the price target from $79 to $92 by Barrington Research, along with the maintained Outperform rating, suggests a positive outlook for LeMaitre Vascular. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100